Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751546 | 1.00 | CA2 (0.55) | CA2FAAHLCKPPARDZDHHC20 | |
| SCHEMBL751208 | 1.00 | CA2 (0.55) | CA2FAAHLCKPPARDZDHHC20 | |
| SCHEMBL10707328 | 0.80 | CA2 (0.59) | CA2FAAHTSHRTHRBCES1 | |
| SCHEMBL13623537 | 0.80 | CA2 (0.59) | CA2FAAHTSHRTHRBCES1 | |
| SCHEMBL14519882 | 0.78 | CA2 (0.63) | CA2FAAHTSHRTHRBCES1 | |
| SCHEMBL27050891 | 0.78 | CA2 (0.63) | CA2FAAHTSHRTHRBCES1 | |
| SCHEMBL1911477 | 0.78 | CA2 (0.63) | CA2FAAHTSHRTHRBCES1 | |
| SCHEMBL11101496 | 0.78 | CA2 (0.63) | CA2FAAHTSHRTHRBCES1 | |
| SCHEMBL8594180 | 0.77 | CA2 (0.56) | CA2FAAHTSHRTHRBCES1 | |
| SCHEMBL752021 | 0.76 | CA2 (0.55) | CA2FAAHTSHRTHRBCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213166-B1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GMBH (DE) | 2012-03-21 | — | — | EP | claimed |
| EP-2213166-A1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GmbH (DE) | 2010-08-04 | — | — | EP | claimed |
| US-20100189811-A1 | Biocide compositions comprising 3-methylisothiazolin-3-one and a haloalkyl sulphone | THOR GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| EP-2216372-B1 | Compounds for preventing Ghost odour | THOR GMBH (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-8287631-B2 | Compounds for preventing ghost odour | THOR GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2213166-B1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-2216372-A1 | Compounds for preventing Ghost odour | THOR GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-2213166-A1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100186631-A1 | Compounds for preventing ghost odour | THOR GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100189811-A1 | Biocide compositions comprising 3-methylisothiazolin-3-one and a haloalkyl sulphone | THOR GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189811-A1 | Biocide compositions comprising 3-methylisothiazolin-3-one and a haloalkyl sulphone | MBTD1, MPST, B2M | CA2 1575/4885FAAH 1508/4885LCK 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.